Similarly, ruxolitinib (another JAK1/2-TKI) had a promising preclinical profile by potently blocking tumor growth in EGFR- and K-RAS-driven lung cancer models and restoring cisplatin-sensitivity to resistant NSCLC cell lines [51,105,106]. Here, KRAS is linked to non-small cell lung carcinoma.